Effect of Luseogliflozin on Myocardial Flow Reserve in Patients with Type 2 Diabetes Mellitus (LUCENT-J Study)

AbstractIntroductionIn patients with type 2 diabetes (T2D), treatment with sodium –glucose cotransporter-2 (SGLT2) inhibitors has been shown to reduce hospital admission rates for heart failure (HF). However, the multiple mechanisms hypothesized and investigated to explain the cardioprotection of SGLT2 inhibitors are not fully understood.ObjectivesThe effect of luseogliflozin on myocardial flow reserve (MFR) in patients with T2D (LUCENT-J) study aims to examine the effects of SGLT2 inhibitors on myocardial perfusion.MethodsThe LUCENT-J study is a prospective, single-center, randomized, two-arm, parallel-group, open-label (i.e., the radiology readers are blinded), active-controlled study. A cohort of 40 patients with T2D with no or stable (with no history of myocardial infarction and with or without previous percutaneous coronary intervention) coronary artery disease will be included. Patients will be randomized in a 1:1 ratio to luseogliflozin or control and treated for 24  weeks. The primary outcome is the change in MFR, as measured by13N-ammonia positron emission tomography/computed tomography, from baseline to 24  weeks after treatment initiation.Planned OutcomesThe LUCENT-J study will elucidate the mechanisms of cardioprotection by SGLT2 inhibitors in patients with T2D.Trial RegistrationJapan Registry of Clinical Trials (JRCTs051220016).
Source: Diabetes Therapy - Category: Endocrinology Source Type: research